Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, PD, and Bioavailability of Branebrutinib in Healthy Subjects
NCT02705989Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of branebrutinib in rheumatoid arthritis (RA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of single oral dose of BMS-986195 up to 8 days and Safety and tolerability of multiple oral doses of BMS-986195 up to 21 days. Started Aug 2016; status: completed.
02
Drugs
branebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02705989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705989.